AI-guided ECG screening to target guideline heart-failure medications and prevent left ventricular dysfunction

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective multicenter analysis using electronic medical records from one academic center and seven regional hospitals in Taiwan from January 2016 to December 2024. Investigators trained an AI-ECG model on over 50,000 paired ECG–echocardiogram recordings (within 7 days) using an 82-layer convolutional neural network with attention, and then applied the model to a cohort with preserved LVEF (≥50%) to stratify high- versus low-risk patients. The team emulated a target trial to compare outcomes in patients who did or did not receive guideline-directed medical therapies (such as ACE inhibitors/ARBs) after AI-based risk classification. The primary outcome was incident left ventricular functional decline, defined as follow-up LVEF ≤40% on echocardiography.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* With an ECG followed by an echocardiogram within a 90-day interval
* With preserved left ventricular ejection fraction (LVEF ≥ 50%)

Exclusion Criteria:

* missing essential variables or ECG lead data
* any prior LVEF \< 50%
* loss to follow-up or death during the 90-day assessment window

Where it's running

• Tri-Service General Hospital
  Taipei, Taipei, Taiwan Recruiting

Study contacts

• Study coordinator: Wei-Ting Liu, M.D.
• Email: wtliucv@gmail.com
• Phone: +886287923311

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using a new cardiac device to treat heart failure with less invasive techniques

  This study is testing a new heart device that can be implanted with less invasive methods to see if it helps people with heart failure feel better and improve heart function.

  Recruiting at 4 sites Berlin Heals GmbH · Banja Luka, Republic of Srbska and 3 other locations · NCT06920030

• Predicting heart function using echocardiography and body composition data

  This study is testing if combining heart ultrasound results with body composition data can help predict heart function in people with and without heart failure.

  Recruiting Yonsei University · Yongin, Gyeonggi-do · NCT06811519

• Hybrid ablation for treating persistent atrial fibrillation

  This study is testing a new hybrid treatment for people with persistent atrial fibrillation to see if it works better than the standard catheter procedure in helping them stay free from heart rhythm problems.

  Recruiting at 5 sites St. George's Hospital, London · Chertsey and 6 other locations · NCT05411614

• Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents

  This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.

  Recruiting Adiyaman University · Adıyaman · NCT07898215

• Safe, long-term finerenone for children and young adults with heart failure and LV dysfunction

  This study tests whether finerenone can be safely used over a long period in children and young adults who have heart failure due to left ventricular systolic dysfunction.

  Recruiting at 13 sites Phase 3 Bayer · Aurora, Colorado and 131 other locations · NCT07192952

• Finerenone versus placebo added to usual care for children with heart failure and reduced left ventricular pumping

  This will test whether finerenone, given with standard heart-failure treatment, helps children aged 6 months to under 18 with reduced left ventricular function compared with placebo.

  Recruiting at 20 sites Phase 3 Bayer · Aurora, Colorado and 132 other locations · NCT07188805

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.